Biogen Idec approves plan to build new factory in Hillerød  

2004.08.16
The board of directors of US biotech company Biogen Idec has approved the plan to build its first large factory outside the US in Hillerød north of Copenhagen

The board of directors of US biotech company Biogen Idec has approved the plan to build a new factory in Hillerød north of Copenhagen, a part of Medicon Valley. The factory will be the company's first large factory outside the US and will primarily produce drugs for the treatment of multiple sclerosis (MS) and psoriasis. Biogen Idec has great expectations for a new drug for MS.

 

Birgitte Thygesen, deputy director of Biogen Idec says the new drug has the potential to become a blockbuster, a term used when annual sales of a drug exceed USD 1bn (DKK 6 bn). Currently the drug is awaiting approval from the US and European health authorities.

 

Biogen Idec is headquartered in Cambridge, MA and employs 4,000 people worldwide. It is the world's third largest biotech company and has a pipeline of 10 products in clinical development. The construction of the new factory in Hillerød has previously been reported to have a budget around DKK 2 bn (USD 320 mn) and 200 new jobs are expected to be created when production starts up around 2008. The news is reported by professional journal Ingeniøren (the Engineer) online.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×